Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,174.71 -0.62 (-0.05%)
Streaming Delayed Price Updated: 11:23 AM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
33 34 Next >
Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review
The major indexes retreated for most of the week on banking fears, 
Via Investor's Business Daily
If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today
Via Benzinga
Why Regeneron Pharmaceuticals Shares Are Trading Lower Today
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned adjusted EPS of $10.09, down 12% Y/Y, beating  
Via Benzinga
Why Regeneron Pharmaceuticals Stock Is Tanking Today
Investors are worried about Eylea's falling sales. 
Via The Motley Fool
Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker
Eylea sales fell and missed expectations in the U.S. 
Via Investor's Business Daily
Regeneron Pharmaceuticals Unusual Options Activity
Via Benzinga
Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector
A pivotal week looks to be shaping up with the usual macro concerns arising, such as a Fed meeting and big earnings waiting just around the corner. One possible path to help navigate around these macro... 
Via Talk Markets
Where Regeneron Pharmaceuticals Stands With Analysts
Via Benzinga
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and its partner Regeneron Pharmaceuticals Inc (NASDAQ: REGN)  
Via Benzinga
Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales
French drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in  
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For April 25
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For April 20
Via Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 5 Years
Via Benzinga
EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial
SAB Biotherapeutics Inc (NASDAQ: SABS) has revealed topline results from the Phase 3 National Institutes of Health's (NIH) ACTIV-2 trial that assessed SAB-185 in non-hospitalized COVID-19 patients at... 
Via Benzinga
Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea
Via Benzinga
The Greatest 7 Blue-Chip Stocks to Buy for Your Portfolio
With so many rumblings in the equities space, investors may be best served taking on the top blue-chip stocks to buy. 
Via InvestorPlace
Regeneron Pharmaceuticals Unusual Options Activity
Via Benzinga
MAIA Biotechnology Touts Positive Data From Healthy Volunteer Study Of Potential Lung Cancer Candidate
Via Benzinga
Investing $1,000 In These 2 Top Stocks Would Be a Great Move
Both have beaten the market over the past year. 
Via The Motley Fool
Regeneron Pharmaceuticals Unusual Options Activity For April 05
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Via Benzinga
JP Morgan Maintains Overweight Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
Via Benzinga
2 Top Growth Stocks That Could Soar This Spring
Exciting news on the way for both of these companies could send their stock prices screaming higher. 
Via The Motley Fool
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
NVIDIA To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday
Benchmark cut the price target for CuriosityStream Inc. (NASDAQ: CURI) from $8 to $4. Benchmark analyst Daniel Kurnos maintained a Buy rating. CuriosityStream shares dropped 22.5% to $1.24 in... 
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For March 28
Via Benzinga
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease. 
Via The Motley Fool
Regeneron Pharmaceuticals, Hess And 1 Of World's Biggest Bank: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management said she is sticking with Regeneron Pharmaceuticals, Inc. 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.